Suministro de Omalizumab (DOE), Nilotinib (DOE), Eltrombopag (DOE), Dabrafenib (DOE), Secukinumab (DOE), Pazopanib (DOE), Trametinib (DOE), Everolimus (DOE) y Midostaurina (DOE)
Awarded
The competition has ended and a winner has been selected.
- Award
- Agreement
- Buying goodsover 1 year
Brief
OSAKIDETZA - Servicio Vasco de Salud - Hospital Universitario Cruces (Impulsora) ha modificado un contrato con Novartis Farmaceutica, S.A. para el suministro de Omalizumab (DOE), Nilotinib (DOE), Eltrombopag (DOE), Dabrafenib (DOE), Secukinumab (DOE), Pazopanib (DOE), Trametinib (DOE), Everolimus (DOE) y Midostaurina (DOE) en Araba/Álava. El contrato tiene una duración de 1 año y un valor final de 4.686.183 €.
Farmasøytisk engroshandel
Result
- NOVARTIS FARMACEUTICA, S.A.Winner
- 0Number of tenders received
- €4,686,183Contract value
Previous winners
Who are you up against?
The suppliers who have won similar contracts at OSAKIDETZA - Servicio Vasco de Salud - Hospital Universitario Cruces (Impulsora)
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Source
No source found in the documents. Check the weight against the tender documents.
From the notice
Suministro de Omalizumab (DOE), Nilotinib (DOE), Eltrombopag (DOE), Dabrafenib (DOE), Secukinumab (DOE), Pazopanib (DOE), Trametinib (DOE), Everolimus (DOE) y Midostaurina (DOE)
Contact
Servicio de Farmaciacontrata@osakidetza.eus- ResultType
- Araba/ÁlavaLocation
- 33600000Main codePharmaceutical products